PRKDC and diffuse large B-cell lymphoma: The combination of ATR, Chk1 and DNA‐PK inhibitors with doxorubicin or cyclophosphamide demonstrates synergistic toxicities in DLBCL cells in association with DNA damage, inhibition of proliferation and apoptosis induction.